Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009 –2016: A retrospective study

Globally, an estimated 240 million people are chronically infected with hepatitis B virus (HBV) [1] and are at an increased risk of developing cirrhosis and hepatocellular carcinoma (HCC) [2]. HBV infection is endemic in China, where more than 120 million people carry hepatitis B surface antigen (HBsAg) and ca. 300 000 die annually of liver cirrhosis or HCC [3]. Both interferon (IFN) and nucleos(t)ide analogues (NAs) are currently used to treat HBV infection [4]. NAs are more widely used as they have fewer adverse effects than IFN [4].

Source: International Journal of Antimicrobial Agents - April 11, 2018 Category: Drugs & Pharmacology Authors: Xianghua Guo, Jushan Wu, Feili Wei, Yabo Ouyang, Qing Li, Kai Liu, Yanjun Wang, Yulin Zhang, Dexi Chen Source Type: research